This week’s Vaccines update highlights clinical progress, early-stage trial initiations, safety data, manufacturing expansion, and advancing immunization strategies across infectious diseases and oncology.
In Today’s Newsletter
Dive deeper
💉 PCV13 safety in pediatric IBD [1] [05 Apr 2026]
https://www.drugtopics.com/view/long-term-study-confirms-safety-of-pneumococcal-vaccination-in-pediatric-patients-with-inflammatory-bowel-syndrome
Context: Multicenter prospective cohort, 279 children and adolescents with inflammatory bowel disease, followed for 24 months.
Key point: PCV13 did not increase exacerbations or disease activity versus unvaccinated peers across treatment groups.
Implication: May influence prescriber choice and payer reviews pending full data.
🏗️ SK Bioscience expands vaccine execution hub [2] [South Korea • 07 Apr 2026]
https://www.businesskorea.co.kr/news/articleView.html?idxno=267221
Context: SK Bioscience said its Songdo Global R&PD Center integrates research, process development, and pilot production.
Key point: The company said GBP410, its 21-valent pneumococcal vaccine with Sanofi, is progressing in global Phase 3, while newer vaccine and mRNA programs advance.
Implication: Signals pipeline investment and modality expansion.
🧬 Moderna previews influenza and RSV revaccination data [3] [06 Apr 2026]
https://feeds.issuerdirect.com/news-release.html?newsid=6767968796143512&symbol=MRNA
Context: ESCMID 2026 presentations cover mRNA-1010 in adults 50 years and older, and mRESVIA in adults 60 years and older.
Key point: Moderna said sequential mRNA-1010 vaccination and heterologous mRESVIA revaccination were well tolerated, with no new safety concerns reported.
Implication: May influence prescriber choice and payer reviews pending full data.
🦠 IAVI starts first-in-human Marburg vaccine trial [4] [US • 06 Apr 2026]
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/iavi-begins-first-in-human-phase-1-trial-of-single-dose-marburg-virus-1154889
Context: Phase 1, randomized, placebo-controlled, observer-blind US study, about 112 healthy adults, six-month follow-up.
Key point: IAVI dosed the first participants with rVSV∆G-MARV-GP, a single-dose Marburg vaccine candidate designed to generate initial human safety and immunogenicity data.
Implication: Signals pipeline investment and modality expansion.
🎗️ Anixa highlights breast cancer vaccine and ovarian CAR-T [5] [US • 07 Apr 2026]
https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-water-tower-research-insights-conference-on-april-14-2026-302735183.html
Context: The update comes via an investor conference announcement, not a primary clinical data release.
Key point: Anixa said its breast cancer vaccine met Phase 1 primary endpoints and generated protocol-defined immune responses in 74% of participants; it also said lira-cel shows positive survival data in Phase 1.
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 Evaxion completes Phase 2 extension for EVX-01 [6] [Denmark • 07 Apr 2026]
https://evaxion.ai/?press_release_id=11056
Context: EVX-01 is a personalized cancer vaccine in advanced melanoma, previously combined with pembrolizumab, then used as monotherapy in year three.
Key point: Evaxion completed the one-year extension as planned and expects to present three-year efficacy data in the second half of 2026.
Implication: May influence prescriber choice and payer reviews pending full data.
🌏 Meiji Seika Pharma opens ASEAN hub in Singapore [7] [Singapore • 07 Apr 2026]
https://www.businesswire.com/news/home/20260407637578/en/Meiji-Pharma-Asia-Commences-Operations-in-Singapore
Context: Meiji Pharma Asia will handle commercialization, marketing, and distribution of pharmaceuticals, including vaccines, across the region.
Key point: Meiji Seika Pharma said its Singapore subsidiary commenced operations on 01 Apr 2026 to strengthen ASEAN expansion.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Vaccine confidence could improve in pediatric inflammatory bowel disease if longer-term safety data continue to hold for PCV13 [1].
- SK Bioscience’s Songdo setup points to faster handoff from vaccine discovery to clinical and pilot-scale execution [2].
- Moderna is shaping the revaccination discussion in influenza and RSV, especially for older adults and repeat seasonal use [3].
- IAVI’s Marburg program adds a human clinical step in an outbreak-prone, high-fatality infectious disease area with no approved vaccine specifically for prevention [4].
- EVX-01 and Anixa’s oncology programs show cancer vaccines remain active across both individualized and preventive approaches [5][6].
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Vaccines archive on our research hub page.
FAQ
What did the pediatric IBD study say about PCV13 safety?
The source says a single dose of PCV13 did not raise exacerbations or disease activity over 24 months versus unvaccinated peers in children and adolescents with IBD [1].
What is SK Bioscience’s main vaccine asset mentioned here?
The item highlights GBP410, a 21-valent pneumococcal vaccine co-developed with Sanofi, which SK Bioscience said is moving through global Phase 3 [2].
What is Moderna presenting at ESCMID 2026?
Moderna said it will present revaccination data for mRNA-1010, its investigational seasonal influenza vaccine, and mRESVIA, its RSV vaccine, in older adults [3].
What is new about IAVI’s Marburg program?
IAVI said first participants have now been vaccinated in a first-in-human Phase 1 study of its single-dose rVSV-based Marburg vaccine candidate in the US [4].
What is the latest milestone for Evaxion’s EVX-01?
Evaxion said the last patient visit has occurred in the one-year extension of its Phase 2 trial, with three-year clinical efficacy data expected in 2H 2026 [6].
What is Meiji Pharma Asia meant to do in Singapore?
Meiji Seika Pharma said the Singapore unit will serve as an ASEAN hub for commercialization, marketing, and distribution of pharmaceuticals, including vaccines [7].
Entities / Keywords
PCV13, 13-valent pneumococcal conjugate vaccine, pediatric IBD, inflammatory bowel disease, Crohn disease, ulcerative colitis
SK Bioscience, Songdo Global R&PD Center, GBP410, Sanofi, pneumococcal vaccine, mRNA platform, RSV monoclonal antibody
Moderna, mRNA-1010, mRESVIA, mRNA-1345, ESCMID 2026, influenza vaccine, RSV revaccination
IAVI, Marburg virus, rVSV∆G-MARV-GP, IAVI C104, Phase 1, outbreak response
Anixa Biosciences, breast cancer vaccine, lira-cel, ovarian cancer CAR-T
Evaxion, EVX-01, personalized cancer vaccine, advanced melanoma, pembrolizumab, Keytruda
Meiji Seika Pharma, Meiji Pharma Asia, Singapore, ASEAN, vaccines commercialization
References